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Abstract: Androgens are the class of sex steroids responsible for male sexual 
characteristics, including increased muscle mass and decreased fat mass. Illicit use of 
androgen doping can be an attractive option for those looking to enhance sporting 
performance and/or physical appearance. The use of in vitro bioassays to detect androgens, 
especially designer or proandrogens, is becoming increasingly important in combating 
androgen doping associated with nutritional supplements. The nutritional sports 
supplement market has grown rapidly throughout the past decade. Many of these 
supplements contain androgens, designer androgens or proandrogens. Many designer or 
proandrogens cannot be detected by the standard highly-sensitive screening methods such 
as gas chromatography-mass spectrometry because their chemical structure is unknown. 
However, in vitro androgen bioassays can detect designer and proandrogens as these assays 
are not reliant on knowing the chemical structure but instead are based on androgen 
receptor activation. For these reasons, it may be advantageous to use routine androgen 
bioassay screening of nutraceutical samples to help curb the increasing problem of 
androgen doping. 
Keywords: androgens; bioassay; designer; doping; mammalian; nutraceutical; steroid; 
supplement; testosterone; yeast 
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Ever since the ancient Olympic Games, athletes have long sought the ability to enhance their 
performance in sports and continue to do so in the modern era of elite competition. Over the past few 
decades, athletes have attempted to enhance their performance with the use of exogenous hormones 
including androgens, erythropoietin and growth hormone. Androgens are the most effective form of 
sports doping and are the most common type of performance enhancing substances detected in 
screening tests. It was not until the 1972 Munich Olympic Games that the International Olympic 
Committee (IOC) introduced screening tests for exogenous androgens [1]. Since then, the World  
Anti-Doping Agency (WADA) enforces the banning of androgens through urine screening to detect 
even trace amounts of an extensive list of banned and prohibited substances which athletes are 
screened for prior, and during, competition. This list relies on screening urine samples with highly 
specific and sensitive techniques such as gas chromatography-mass spectrometry (GC-MS). 
For some athletes, the prospect of success outweighs the health and unethical concerns of sports 
doping. In an attempt to bypass screening methods, designer androgens have been created that have 
different chemical structures to known androgens and, therefore, cannot be easily detected by GC-MS. 
However, because designer androgens have biological activity they activate the androgen receptor 
(AR), and therefore can be detected by androgen bioassays. Therefore, androgen bioassays may prove 
to be a suitable tool for routine screening of nutraceutical or biological samples suspected to contain  
an androgen. 
2. Steroid Hormones 
Steroid hormones include the sex hormones, glucocorticoids, and mineralocorticoids. Within the 
family of sex hormones are the androgens, estrogens, and progestogens. All of the steroid hormones 
bind to their own specific receptor, which may be cytosolic or nuclear, to induce changes within a cell. 
All natural steroid hormones are synthesized from cholesterol in the adrenal glands and/or gonads. 
Some steroid hormones are further metabolized in the liver, peripheral and/or target tissues. As their 
precursor is cholesterol, they are hydrophobic in nature which allows them to pass easily through cell 
membranes. Once synthesized, the steroid hormones are carried in the blood stream bound to carrier 
proteins such as albumin, steroid hormone-binding globulin (SHBG) or corticosteroid-binding globulin 
to target tissues. 
The androgen produced in the highest concentration in the body is testosterone (T). This is a 19-C 
steroid that has androgenic and anabolic effects within the body. T is primarily produced in the gonads 
but a small amount is produced in the adrenal cortex or from the peripheral conversion of 
androstenedione. T production is much greater in males than in females (5,000–7,000 µmg/day versus 
300 µmg/day) [2]. In males, T is primarily produced by the Leydig cells in the testes whereas in 
females, the primary production of T occurs in the Theca cells of the ovaries. In both sexes, small 
amounts come from the adrenal cortex and the peripheral conversion of androstenedione. 
T acts in the body by acting directly through the AR or indirectly via metabolism to other sex 
steroids. T can be aromatized to estradiol (E2) which activates ER-α and/or ER-β. Alternatively, T can 
be irreversibly converted to the more potent 5α-dihydrostestosterone (5α-DHT) by the enzyme  
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5α-reductase. T has many physiological actions in the body. It acts on muscles to stimulate growth and 
maintenance, it promotes bone development while inhibiting bone resorption, it increases red blood 
cell and hemoglobin levels, augments libido and erectile function, enhances mood and cognition, and 
induces lipolysis. Low testosterone levels or deficit in androgen action induces frailty, sarcopenia, poor 
muscle quality, muscle weakness, hypertrophy of adipose tissue and impaired neurotransmission.  
3. Myotrophic Action of Androgens 
The myotrophic effects of androgens on muscle strength and mass are the main reason for their 
popularity among androgen users. Androgens also increase lean body mass, decrease fat mass, enhance 
performance, sustain intensive training periods, and can improve appearance [3,4]. The effects on lean 
body mass were shown by treating young men with a gonadotropin-releasing hormone (GnRH) 
analogue that suppressed endogenous T production. These men showed decreased rates of whole body 
protein synthesis, muscle strength and fat oxidation, together with an increased fat mass [5]. When T 
was replaced through supplementation, there was a restoration of muscle size and strength with a 
concomitant reduction in fat mass [6]. 
Androgens including T increase muscle fiber hypertrophy in human skeletal muscle by enhancing 
protein synthesis. This occurs via the activation of satellite cells and the promotion of myonuclear 
accretion when existing myonuclei become unable to sustain further enhancement of protein synthesis [7]. 
The use of androgen therapy during aging is primarily to promote muscle strength by improving or 
maintaining muscle mass. 
Androgens are used clinically to treat a range of different human disorders. Among these are several 
catabolic conditions such as obstructive pulmonary disease [8], severe burn injuries [9], and also  
HIV-related muscle wasting [10]. It can also be used to treat a number of conditions resulting from 
deficiencies in androgen production, such as constitutional growth retardation and hypogonadism [11]. 
Androgen therapy can be administered orally, by intramuscular injection, and as gels and creams. 
Synthetic alkyl esters of androgens have been used therapeutically for decades due to their high 
potency and prolonged action [12]. The realization that androgen administration can augment muscle 
hypertrophy has led to the abuse of androgens to increase muscle size, strength and sport performance. 
One of the earliest accounts of androgen abuse dates back to the 1950s where Soviet weightlifters were 
allegedly taking testosterone [13]. While the abuse of androgens is more commonly associated with the 
weightlifting industry, their use is widespread amongst many sports, both at the elite and amateur 
levels. Alarmingly, androgen use is not limited to adults, with reports that school-aged children use 
androgens [14]. 
For bodybuilding and enhanced athletic performance enhancement, it is common that very high 
doses of androgens are consumed [15]. Moreover, it is common practice to employ “stacking” regimes 
where a number of different androgens and/or metabolism inhibitors are simultaneously consumed. 
This can lead to serious clinical consequences such as abnormal liver function, gynocomastia, severe 
psychological or psychiatric disorders, increased risk of cardiovascular disease; and in females, 
menstrual disorders and virilization [16]. Many of the androgens that are used are 17-methylated 
compounds and are associated with high-liver toxicity [17]. 
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4. Androgens and the Nutritional Supplement Market 
During recent years, the nutritional supplement market has expanded and in 2006, the world-wide 
market was estimated to be worth more than US$ 60 billion [18]. The use of supplements is popular in 
the general population; however, athletes corner the market with 44–100% prevalence, dependent on 
age, gender, level of competition and the type of sport [19]. Whilst vitamins, minerals, proteins and 
creatine, are not prohibited by WADA, the problem arises when supplements contain additives that are 
not on their label. This can occur inadvertently through cross-contamination from a production line 
and/or transport in unclean containers [20] or it can occur through direct addition. This level of 
contamination can be sufficient to create a positive doping test. For example, 634 nutritional 
supplements purchased from 13 different countries were analyzed with mass spectrometric methods 
(GC/MS, LC/MS/MS) for undeclared doping substances and 15% of these minerals, vitamins, creatine 
or protein supplements contained androgens (mostly prohormones) that were not declared on the  
label [21]. In another example, bioassays were used to screen a range of nutritional supplements for 
hormonal activity and found that for 63 supplements, only 13 were negative for estrogenic activity and 
that only 18 were negative for androgenic activity. All of the other supplements showed agonistic, 
partial agonistic and/or antagonistic hormone activities, indicating that these health food products 
contain hormonally active constituents [22]. Since 2002, nutritional supplements have been found to be 
intentionally spiked with androgens at concentrations higher than 1 mg/g. The androgens found include 
metandienone [23], stanozolol [24], boldenone [24], oxandrolone and dehydrochloromethyltestosterone [20]. 
These androgens were either not declared, or were declared but with non-approved names on the 
labels. The nutritional supplements can be purchased without restriction by telephone order or internet 
purchase and are delivered by ordinary mail. This allows easy access by the general population for 
non-medical reasons. Not only do sport nutritional supplements face the problem of androgen spiking, 
either deliberate or accidental, but “natural” products have also been found to contain hormonally 
active substances. For example, a herbal product used for the treatment of high level prostate-specific 
antigen (PSA) was found to contain an estrogenic substance, diethylstilbestrol (DES) using a yeast 
estrogen bioassay, together with nuclear magnetic resonance (NMR) and liquid chromatography/ 
time-of-flight MS (LC/TOFMS). This was identifiable clinically because of the development of 
gynocomastia [25]. Therefore, it is evident that the intentional or unintentional addition of hormonally 
active substances is an ongoing problem. It is important then that methods are available for the 
exquisite detection of these hormonally active substances, especially those that are androgenic. 
5. The Androgen Receptor (AR) 
Androgens primarily exert their effects by binding to and activating a specific receptor, AR, which 
is expressed in most cells. The AR is a 110 kDa protein to which the natural androgens, T and DHT, 
bind with high affinity [26]. In its inactivated state, AR is bound in the cytoplasm to heat shock 
proteins. When androgens bind to the AR via the ligand binding domain (LBD) of the AR, a 
conformational change is induced that promotes the dissociation of the heat shock proteins and AR 
subunits dimerize to form a homodimer. The dimerized AR complex translocates to the nucleus where 
it binds to androgen response elements (ARE) in the regulatory regions of androgen target genes [27] 
Sensors 2013, 13 2152 
 
 
(Figure 1). Binding of AR to the ARE occurs via the DNA binding domain (DBD). Regulatory 
cofactors interact with AR to promote DNA binding. Transcriptional activation by AR also involves 
cofactors that modify the chromatin structure and histone complexes in the DNA surrounding the  
ARE [26,28]. This is important because the ARE can be located distantly from the transcription start 
site of androgen-regulated genes, therefore, cofactors that alter DNA shape and flexibility are needed 
for AR to augment transcription [29]. 
Figure 1. The androgen response in cells. 
 
Androgens diffuse through the plasma membrane into the cytosol where they bind to the androgen 
receptor (AR). The androgen receptor is held in the cytosol by heat shock proteins (HSP) and other 
cofactors. The binding of androgens to the androgen receptor induces a conformational change in 
the receptor that frees it from the inhibitory factors and exposes a nuclear localization signal. The 
androgen/AR complex translocates to the nucleus where the receptor dimerizes and binds to the 
androgen response elements (ARE) located in the regulatory regions of target genes. Once bound to 
the DNA, AR enhances gene transcription by RNA polymerase. 
6. Androgen Detection Methods 
6.1. Mass Spectrometry (MS) 
In an effort to control androgen use for enhanced sport performance, WADA screens biological 
samples for the presence of androgens, metabolites, and/or masking agents. Professional athletes are 
tested both during, and before, competition. There are a number of routine screening tests that are used 
to detect exogenous androgen administration, including measuring the testosterone to epitestosterone 
(T/E) ratio by GC-MS [30]. Epitestosterone is a co-secreted product of T and normally is present in 
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urine at levels similar to testosterone. If exogenous T is administered this will elevate the T level, but 
not the epitestosterone level. This test is complicated by the fact that the values of testosterone and 
epitestosterone vary greatly between individuals, and therefore, any sample that meets any one of the 
following criteria will be sent off for further analysis using Isotope Ratio Mass Spectrometry (IRMS): 
(1) T/E value greater than or equal to 4; (2) concentration of T or E greater than 200 ng/mL;  
(3) concentration of androsterone or etiocholanolone greater than 10,000 ng/mL; and (4) concentration 
of DHEA greater than 100 ng/mL. If a sample is submitted for further evaluation by IRMS, the 13C/12C 
ratio of the androgen will be measured. This is because commercially produced androgens will have 
higher 13C levels compared with endogenous androgens [30]. 
Synthetic androgen use is screened by GC-MS. This is possible because each synthetic androgen 
has a distinctive chemical structure on GC-MS that is readily identifiable and can be matched to a 
catalogue kept by WADA. Even trace amounts of synthetic androgen intake are detectable months 
after the last administration with GC/MS able to detect concentrations in the pg/ml range. The GC-MS 
screening tests are very sensitive and specific for known androgens on the WADA list. However, these 
screening tests cannot provide a complete detection of all androgens because they are unable to detect 
designer androgens. 
6.2. Receptor Binding (Competitive) Assays 
Receptor binding assays are based on the binding affinity of a ligand for its receptor. For this assay, 
purified receptor is immobilized on a column or suspended in a homogenate and to this, radiolabeled 
testosterone of known concentration is added. For the test, the suspect molecule is added to the 
radiolabeled testosterone, and it is measured whether the unknown molecule displaces the binding of 
the testosterone. If there is displacement then the unknown molecule has AR binding affinity. This 
type of assay only measures binding to AR and therefore is not able to differentiate between agonist 
and antagonist activity, or if any activity per se. Receptor binding assays require the use of 
radiolabelling, which presents a hazard if used as a routine screening test. These assays can be 
developed as high-throughput and are relatively easy to perform. To date, they have been used in a 
number of applications, including screening animal feed for growth hormones [31] and screening for 
potential endocrine disrupting chemicals (EDCs) [32,33]. They can also be used to investigate the 
potential potency of anabolic steroids by assessing the ability to bind to AR [34,35]. 
6.3. Limitation of Structure-Based Methods for Screening of Androgens 
It has been discovered that designer androgens have been synthesized with the specific intent of 
being undetectable by standard screening, allowing athletes to use androgens for enhanced sport 
performance. For example, in 2002, Catlin et al. discovered that norbolethone, a never-before marketed 
androgen, was present in an athlete’s urine sample [36]. It was identified with GC-MS based on 
chemical signatures of norbolethone that were established in the 1960s when norbolethone was  
tested in clinical trials but later not marketed. Since then, other designer androgens have been  
detected, primarily found in nutritional supplements, marketed illicitly over the internet. In 2003, 
tetrahydrogestrinone (THG), a modified progestin, was discovered. A yeast-based in vitro androgen 
bioassay confirmed that THG was a potent androgen, capable of activating AR [37]. Later, THG was 
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detected in a human urine sample using a bioassay in combination with LC/TOFMS [38]. Structural 
modification of either the T or progesterone background could produce an almost limitless number of 
androgenic steroids with structures that are not on the WADA detection list [39]. Also in development 
for clinical use are non-steroidal androgenic molecules (SARMs) that too will pose a risk to sports 
doping because of their ability to activate the AR. 
7. Androgen Bioassays 
Androgen bioassays used for detection differ from the techniques described above because they 
mimic AR function and are not dependent on chemical structure. There are a number of different 
bioassays ranging from those based on whole animals to those based on mammalian or yeast cells. The 
Hershberger assay is an example of an in vivo androgen bioassay. The endpoint of this assay is a 
measured increase in the weight of androgen-dependent tissues. It is based on orchidectomised animals 
that produce little endogenous sex steroid hormones. These animals are treated with the test compound. 
If the test compound is androgenic, it will promote growth of androgen-dependent tissues [40]. As this 
is an in vivo assay, metabolism of test molecules can also be tested by analyzing metabolites present in 
the blood stream and/or urine. As metabolism occurs upon treatment, this assay cannot be used to 
screen for activation or inactivation of androgens but it does allow the dissection of anabolic and 
androgenic effects of the test molecule or its metabolites. An assay based in animals is not feasible for 
routine sports doping screening in WADA laboratories. This has led to the development of in vitro 
cell-based androgen bioassays to screen for androgenic compounds. 
In vitro cell-based bioassays are widely used to detect androgenic molecules. They were first 
developed to test environmental pollutants (endocrine disrupting chemicals, EDCs) for their ability to 
alter normal hormonal function. Many substances including detergents (nonylphenol and other 
alkylphenols), plastics (bisphenol A), pesticides, insecticides, and even pharmaceutical wastes such as 
birth control tablets (ethinylestradiol) are now classified as EDCs [41]. In vitro yeast androgen 
bioassays can be used in combination with other detection methods such as ultra high performance 
liquid chromatography combined with time-of-flight-tandem mass spectrometry (UHPLC/TOFMS) or 
liquid chromatography screening method. In the first example, herbal mixtures and sport supplements 
were screened using the yeast yEGFP bioassay, after sample preparation to activate inactive  
pro-androgens, androgen esters and conjugated androgens. The samples that tested positive were  
then analysed by UHPLC/TOFMS which led to the positive identification of nortestosterone 
phenylpropionate, testosterone cyclohexanecarboxylate and methyltestosterone in herbal supplements 
and methylboldenone, testosterone and the androgen esters, methyltestosterone propionate or 
testosterone isobutyrate, testosterone buciclate, and methylenetestosterone acetate. In the second 
example, 18 different dietary supplements that had been previously analysed with liquid 
chromatography-tandem mass spectrometry method (LC-MS/MS) were screened with the yeast 
yEGFP bioassay. LC-MS/MS showed 11 samples positive for androgens- a finding that was 
corroborated by the bioassay. However, of the seven that were negative using LC-MS/MS, two were 
positive when screened by the bioassay. Subsequently, LC/TOFMS identified 4-androstene-3β,17β-
diol and 5α-androstane-3β,17β-diol. These assays show that bioassay guided analysis is a useful 
procedure to detect, isolate, and identify unknown androgens in suspected samples. Moreover, it shows 
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that bioassays can detect androgens in samples where LC-MS/MS could not, highlighting that 
bioassays have a valuable role in the fight against doping. 
In vitro cell-based bioassays are also used to test for illegal substances such as growth promoters 
that are given to livestock. These androgens or androgen-like molecules enhance the growth of the 
animals and are used as a means to increase profit. Naturally occurring steroids such as testosterone or 
synthetic androgens such as 19-nortestosterone, trenbolone acetate, and medroxyprogesterone are  
used to illicitly augment growth of animal livestock [42,43]. In addition, prohormones such as 
dehydroepiandrosterone (DHEA) are being used, and these are often hard to detect if they have been 
exogenously administered [44]. GC-MS-based screening of material such as meat extracts, feed or 
urine may fail to detect these substances because deconjugating steps are required prior to GC-MS 
analysis and these processing steps can destroy the structures. GC-MS may also fail to detect novel 
structures or those with unknown metabolic profiles. Bioassays can complement the screening of 
samples as they are capable of detecting hormonally active compounds in prepared extracts and if the 
appropriate host cell is used for the bioassay such as hepatocytes then such assays may also detect 
prohormones [43,45,46]. For these reasons, bioassays are ideal for the detection of androgens or 
proandrogens added to nutritional supplements. 
Cell-Based Androgen Bioassays 
Cell Proliferation Assays 
Cell proliferation assays can be used to measure the hormonal activity of a suspected agonist (or 
antagonist) in a sample because hormones, via their specific receptors, stimulate cell growth. In these 
assays, radioactive-labeled nucleotides are included in the culture media that become incorporated into 
DNA as cells proliferate. The radiolabel that incorporates into cells is a direct measurement of cell 
proliferation. These assays can measure both agonist and antagonist activity, as an agonist for the 
receptor of interest can stimulate cell growth, whereas an antagonist will block cell growth in the 
presence of an agonist. To date, this type of bioassay has not been extensively used to screen for 
androgens, however, it is the basis of the E-screen, which uses the human breast-cancer cell line 
(MCF-7) to screen for xenoestrogens [47]. This assay is relatively simple to perform and is amenable 
to high-throughput readouts. However, results can be confounded by cell expression of other receptors 
(such as AR and glucocorticoid receptor) that induce non-specific cell proliferation. The assay relies 
on cell growth and, therefore, it can take days to produce results [48]. Thus, it is not really feasible for 
use in sport doping laboratories. 
In Vitro Androgen Receptor-Reporter Gene Bioassays 
In vitro androgen receptor-reporter gene bioassays exploit the natural signaling pathway of 
androgens. Firstly, a host cell is chosen because it minimally or does not express endogenous AR. The 
host cell is then genetically manipulated to express AR. Secondly, the host cell is transformed with a 
reporter vector in which a minimal promoter is driven by either AREs or MMTV elements (that also 
bind AR) that, together, regulate the expression of a reporter enzyme or protein (e.g., luciferase, green 
fluorescent protein (GFP), secreted alkaline phosphatase (SEAP) or β-galactosidase). When the 
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genetically transformed cell is exposed to androgens, the androgens activate AR that, in turn, binds to 
the cloned ARE or MMTV and drives the expression of the reporter enzyme or protein, which can 
easily be assayed (Figure 2). 
Figure 2. Yeast and mammalian cell-based androgen bioassays. 
 
Both bioassays are based on the transfection of two plasmid vectors. One plasmid vector is an 
androgen receptor (AR) expression vector that allows high level constitutive expression of AR 
within cells that contain no (yeast) or low level (mammalian) of endogenous AR. The second 
plasmid vector is an androgen response element (ARE) driven reporter gene vector. For yeast cells, 
the most efficient reporter gene, to date, is β-galactosidase. For mammalian cells, a number of 
reporter genes are used, with secreted alkaline phosphatase (SEAP) a favored choice because of its 
ease of detection. Yeast cells do not express androgen metabolizing enzymes. Mammalian cells 
such as human hepatocytes express a number of different metabolizing enzymes including 
aromatase, 5α-reductase and hydroxysteroid reductases (HSD). 
The two major host cells are yeast or mammalian cells. The advantages of the yeast cell-based 
bioassay are that yeast cells are relatively easy and cheap to grow and are suitable for high-throughput 
applications. To date, yeast cell bioassays have been used to test urine samples for androgen detection, 
nutraceutical extracts for androgen detection, cattle hair samples for steroid esters as well as testing  
for the androgenic potency of pure preparations of many androgens, designer androgens and  
progestins [37,49–52]. The most commonly used yeast cell-based bioassay is that in which the 
laboratory yeast strain, Saccharomyces cerevisiae, is co-transformed with an AR expression vector and 
an ARE/β-galactosidase reporter gene vector [53]. For this assay, the yeast cells are cultured in 
selective minimal media and then exposed to the steroid/steroid extract of interest for 24 h before cells 
are lysed and β-galactosidase activity measured. This approach is reliable and reproducible, with an 
EC50 of ~5 nM so therefore able to measure T concentrations within a male physiological range, 
although they are less sensitive than GC-MS that is able to detect steroids in the pM range. Yeast cells 
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are exceptional for monitoring pure androgenic potential of test molecules or extracts as they do not 
express metabolizing enzymes. This, however, means that yeast cell based assays will not detect 
activity of any molecule that requires activation (that is a prohormone) or a molecule that may be 
inactivated in vivo. Therefore, yeast cell-based assays per se cannot be used as a sole means of 
androgen detection of unknown samples.  
The traditional AR/ARE/β-galactosidase reporter assay involves long incubation times (24 h),  
pre-assay preparation and post-incubation cell lysis steps. To try and improve on this assay, other 
reporter genes have been used in yeast cell androgen bioassays. For example, luciferase has been used 
as its detection requires no cell lysis step with the substrate, luciferin, directly added to the yeast 
culture for the measurement of enzyme activity [54]. This assay is quick, easy to use, however, it has 
lower sensitivity with an EC50 of ~10 nM for T [54]. Both the luciferase and β-galactosidase  
enzyme-based assays may have issues due to the build-up of artifacts, or if the compounds tested 
inhibit enzyme activity or stabilize the enzyme [55]. To address these issues, a simple fluorescent 
measurement to screen has been generated that utilizes an ARE-yEGFP (yeast enhanced green 
fluorescent protein) reporter construct. yEGFP as the reporter is superior to β-galactosidasae or 
luciferase because no enzyme substrate is required instead just a simple fluorescent readout, making 
the assay cheaper, quicker and easier to complete. However, this assay shows a lower sensitivity with 
an EC50 of 50 nM for T [45,51]. Therefore, to date, it remains that the most sensitive of the yeast  
cell-based bioassays is that based on the original AR/β-galactosidase enzyme in S. cerevisiae. 
In Vitro Mammalian Cell-Based Androgen Bioassays 
In similar fashion to yeast cell-based bioassays, a number of mammalian cell bioassays have been 
developed. These harbor different reporter enzymes/proteins and/or are established in different cell 
types. The mammalian cell-based bioassays involve stable transfection of the cell with an AR 
expression vector and an ARE/minimal promoter/reporter gene vector. The reporter enzyme/protein 
used for mammalian cell assays include luciferase, green fluorescent protein and SEAP (see Table 1). 
A common feature of mammalian cell-based bioassays is that they show higher sensitivity than yeast 
cell-based bioassays, with reported EC50 values often 10-fold lower. However, due to the expression of 
endogenous receptors they show lower specificity because of crosstalk between receptors [56]. 
Moreover, mammalian cells express a range of androgen metabolizing enzymes including aromatase, 
5α-reductase, 17β-hydroxysteroid reductase and 3α-hydroxysteroid reductase [52], that can alter the 
potency of the test substrate, either activating it making it a stronger androgen or deactivating it 
making it a weak androgen. The benefits of the metabolizing enzymes are that they allow for 
prohormones to be detected as well as offering insight into how a test steroid/extract may behave  
in vivo. However, the metabolism capacity of mammalian cells may be limited by the type of host cell 
as different cell types express metabolizing enzymes at different levels and the passage number of the 
cell culture as some cells are reported to switch off expression of some metabolizing enzymes during 
in vitro culture. Thus, in vitro metabolism in cultured cells may not reflect in vivo metabolism. To date, 
the literature reports ambiguity with EC50 sensitivities and specificities most likely due to these 
metabolizing effects [57–63]. Testosterone, for example, has been shown to exhibit very sensitive 
responses using a mouse mammary tumor virus (MMTV)/luciferase construct in human kidney cells 
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(HEK293) with an EC50 of 0.3 nM [57]. By contrast, this same construct is less sensitive in Chinese 
hamster ovary (CHO) cells with an EC50 of 1.06 nM [58]. In a recent study by Akram et al. [52], the 
importance of choosing the right reporter construct can be further emphasized, whereby even using  
the same cell type (HEK293), the EC50 values of the tested androgens differed between the 
MMTV/luciferase bioassay and the enhancer/ARE/SEAP showing EC50s of 136 ± 60 nM and 450 ± 24 nM 
respectively for a known androgen, formadrol. Reported variations in sensitivities across bioassay 
types (yeast and mammalian) for various androgens are shown in Table 1. Thus, mammalian  
cell-based assays are more sensitive than yeast cell-based assays, however due to the potential 
metabolism of androgens they can be less robust than yeast cells in defining a true androgenic potency 
and results may be confounded by metabolism effects that must be considered [52] and for a detailed 
analysis of a test extract/steroid are best combined with a yeast cell-based assay to determine baseline 
androgen potency. 
Table 1. Sensitivities of various androgen bioassays. 
Androgen Construct Cell line/species EC50 (nM) Author 
Testosterone MMTV/Luciferase AR HEK293 0.3 Roy, P. 2006 [56] 
ARE/Luciferase U2-OS 0.86 Houtman, C. 2009 [57] 
ARE/Luciferase CHO 1.06 Araki, N. 2005 [58] 




S. cerevisiae  15 Lee, H. 2003 [59] 
ARE/GFP S. cerevisiae  23 Beck, V. 2008 [60] 




S. cerevisiae  4.8 Lee, H. 2003 [59] 
ARE/GFP S. cerevisiae  16 Beck, V. 2008 [60] 
Methyltestosterone ARE/Luciferase CHO 0.7 Araki, N. 2005 [58] 
ARE/GFP S. cerevisiae  1.2 Beck, V. 2008 [60] 
4-Androstenedione ARE/Luciferase CHO 1.02 Araki, N. 2005 [58] 
AR-CALUX U2-OS 4.5 Sonneveld, E. 2005 [61] 
ARE/Luciferase S. cerevisiae  500 Michelini, E. 2005 [62] 
The detection of prohormones or an understanding of potential metabolism of test extracts is central 
for the analysis of nutritional sport supplements. Mammalian cell lines may be limited in their 
metabolic capacity, compared to in vivo metabolism. To address this, a liver tissue metabolism step has 
been combined with the yeast AR/ARE/EGFP-based bioassay [64,65]. In this two-step assay, test 
extracts are first incubated with a bovine liver S9 fraction, the extract recovered, and then exposed to 
the yeast AR bioassay. As the liver tissue is whole, it is expected that this ex vivo approach will mimic 
the in vivo capacity for enzymatic conversions of steroids and therefore detect both prohormones 
and/or strong androgenic metabolites. In another example of introducing a pre-metabolism step prior to 
testing with a yeast AR bioassay to allow for prohormone or androgen metabolite detection, samples 
were pre-treated with a Helix pomatia enzyme mix to activate inactive hormone conjugates including 
sulphates, glucuronides and glycosides [46]. This example was in the setting of feed supplementation, 
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rather than nutraceutical supplements, however, it is possible that a similar approach could be used to 
detect such conjugates if they were components of nutraceuticals. 
8. Feasibility Issues with Current Cell Based Androgen Bioassays 
At present no androgen bioassay has been endorsed by sport doping laboratories for high 
throughput screening for androgens in nutritional sports supplements or biological samples. Yeast  
cell-based bioassays are exceptional because of their specificity, ease of use (especially the  
yEGFP-based system), and they are cost-effective. The downside of yeast cell-based bioassays are they 
are less sensitive than mammalian cell-based bioassays, and they are unable to detect prohormones or 
potent androgenic metabolites because they have no metabolic capacity. To this end, the combination 
of using mammalian cell-based bioassays or liver tissue metabolism steps with the yeast cell-based 
bioassay may be the best approach for detection of androgens, potential androgenic metabolites, and 
proandrogens in nutritional sports supplements. Mammalian cells may be limited in their capacity to 
mimic in vivo metabolism with differential (and perhaps decreasing) expression of necessary 
metabolizing enzymes. Liver tissue may be less limited in the full complement of metabolizing 
enzymes, however, this approach requires animal sacrifice to obtain liver slices and this may therefore 
limit the feasibility of this approach for high throughput screening in WADA-accredited laboratories. 
9. Conclusions 
Current WADA screening methods, such as the highly sensitive GC-MS, fail to detect designer 
androgens of unknown structure. Novel designer androgens are being increasingly incorporated in 
nutritional supplements, allowing athletes to use androgens to enhance performance. In vitro androgen 
bioassays are able to detect designer androgens, and in some cases, proandrogens, as they do not 
depend on structure analysis, but instead exploit the natural pathway of androgen signaling via AR 
activation. While not as sensitive as GC-MS, some in vitro androgen bioassays can detect physiological 
concentrations of testosterone, and therefore, can detect androgens at the supraphysiological levels 
used in sports doping. Importantly, a combination of yeast and mammalian cell-based or liver tissue 
and yeast AR bioassays can comprehensively screen for known androgens, designer androgens, and 
proandrogens. Therefore, further development of in vitro androgen bioassays to decrease testing times, 
processing steps such as further development of yEGFP assays and improved detection limits 
(sensitivity) could help to combat the war against androgen use. By incorporating routine bioassay 
screening of nutritional supplements, blatant and inadvertent androgen doping may be reduced. 
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